GE Healthcare has received U.S. Food and Drug Administration (FDA) clearance for its DaTscan (ioflupane I-123 injection) radiopharmaceutical agent.
Used with SPECT scans, DaTscan is designed for the detection of dopamine transporters in the brains of adult patients with suspected Parkinsonian syndromes, according to the Chalfont St. Giles, U.K.-based vendor. DaTscan can help physicians evaluate neurodegenerative movement disorders, such as idiopathic Parkinson's disease; it may be used as an adjunct to other diagnostic evaluations to help differentiate essential tremor from tremor due to Parkinsonian syndromes, GE said.
The FDA cleared DaTscan after reviewing the radiopharmaceutical in its priority review program, GE said.
Related Reading
GE touts flutemetamol studies for AD, January 14, 2011
GE brings imaging to Fiesta Bowl title game, January 10, 2011
GE taps new European head, January 5, 2011
GE forms joint ventures in Russia, December 27, 2010
GE expands InSite OnWatch, December 17, 2010
Copyright © 2011 AuntMinnie.com
